Opportunities and challenges in the field of systemic amyloidosis can be grouped into 4 categories. First, a deeper understanding of the pathogenesis of the disease is required. Second, a greater awareness of the disease, which will lead to an earlier diagnosis, is imperative. Third, end points for interventional trials are required to convey us to our fourth aspirations, which are novel therapies for patients with light chain amyloidosis.
Keywords: Early diagnosis; Outcome measures; Pathogenesis; Systemic amyloidosis; Trial design.
Copyright © 2020 Elsevier Inc. All rights reserved.